WASHINGTON (AP) – Federal health officials have approved the first pill to treat all major forms of hepatitis C, the latest in a series of drug approvals that have reshaped treatment of the liver-destroying virus.READ MORE: 'I Just Think It's A Bad Dream': Parent Reacts After Pregnant Mother Of 4 Killed On Texas Highway
The Food and Drug Administration approved the combination pill from Gilead Sciences for patients with and without liver damage. The agency has approved a number of hepatitis C drugs in the last three years but all were targeted to specific strains of the virus or patients with various stages of liver disease.READ MORE: Denton Police Mourning Passing Of Detective Rodney Mooneyham To COVID
Epclusa, the new pill from Gilead Sciences, combines the company’s first hepatitis drug, Sovaldi, with a new drug that attacks the virus using a different mechanism.
Gilead’s hepatitis pills have raked in billions of dollars by replacing an older approach that involved a grueling pill-and-injection cocktail.MORE NEWS: Dak TD Pass To CeeDee Lifts Dallas Cowboys To 35-29 Overtime Win Over Patriots
(© Copyright 2016 The Associated Press. All Rights Reserved. This material may not be published, broadcast, rewritten or redistributed.)